Dr. Lynette Ngo
Experience:
15 years
Language:
English
Location:
Singapore

About

MBBS (S’pore), M Med (Int Med), MRCP (UK), Dip Palliative Med (Aus) Dr Lynette Ngo is a medical oncologist who specializes in women’s cancers – breast and gynaecologic cancers including ovary, endometrial, uterine and cervical cancers.

Qualifications

Dr Ngo graduated from National University of Singapore in 1996. She further pursued a Master of Medicine degree in Internal Medicine and obtained her membership of the Royal College of Physicians in UK in 2002. She received her post graduate Diploma in Palliative Medicine from Edith Cowan University in Australia in 2006 and obtained her specialist accreditation in medical oncology from the Academy of Medicine, Singapore in 2007. She is a member of the American Society of Clinical Oncology (ASCO), European Society of Clinical Oncology (ESMO), Asian Society of Gynaecologic Oncology (ASGO) and Singapore Society of Oncology (SSO). She serves on the Singapore Cancer Network (SCAN) guidelines committee. Prior to Curie Oncology, Dr Ngo had been practising at National Cancer Centre, Singapore (NCCS) from 2005 to 2012 before moving to Raffles Cancer Centre, Raffles Hospital from 2012 to 2019. Aside from being a Clinical Tutor at the Yong Loo Lin Medical School, she was also a Visiting Consultant to both KKWCH Gynaecologic Cancer Centre and KKWCH Breast Centre as well as to Khoo Teck Puat Hospital. In addition, she spent 5 years caring for patients in hospice home care and in-patient hospice services in the community prior to joining NCCS. Dr Ngo has also completed the Intensive Course in Cancer Risk Assessment at City of Hope Hospital in California, USA from Oct 2017 to Mar 2018. She established the Hereditary Cancer Risk assessment clinic and genetic counselling in Raffles Hospital.

Awards and publications

Dr Ngo’s areas of interest are in breast and gynaecologic cancers, hereditary cancers and genetic counselling, psychosocial oncology and palliative medicine, in addition to general medical oncology. In pursuing her sub-specialty interest in gynaecologic cancers, Dr Ngo was awarded the Health Manpower Development Programme Award to spend a year at the Gillette Center for Gynecologic Oncology at Massachusetts General Hospital (MGH), USA. In collaboration with the MGH gynaecologic oncology team, she designed and conducted several investigator-initiated clinical trials, testing novel drugs and treatment strategies in subsets of gynaecologic cancers with molecularly defined pathways. She had received a grant from the Singhealth Foundation for her research work and was involved in multiple clinical trials in Raffles Hospital focusing on breast and gynaecologic cancers. She has contributed to numerous publications in peer reviewed journals and written book chapters.

Speciality

  • Medical Oncology

Expertise

  • Breast Cancer
  • Gynaecological Cancer

Trials Specialist is participating in

4 trials shown

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally re

Study number:
NCT05374512
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Immunotherapy, Chemotherapy

Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer

Primary Objective: To determine whether Amcenestrant (SAR439859) in combination with palbociclib improvesprogression free survival (PFS) when compared with letrozole in combinatio

Study number:
NCT04478266
Cohorts:
1
Study phase:
3
Overall status:
Active, not recruiting
Study type:
Targeted therapy, Hormonal therapy

Astrazeneca

Key trial

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor

Study number:
NCT04494425
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Targeted therapy, Biomarker

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or withou

Study number:
NCT04269200
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Immunotherapy, Targeted therapy